Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 12, 2017, Pages

  MacVane, Shawn H ^a,b   Pandey, Ruchi ^c   Steed, Lisa L ^b   Kreiswirth, Barry N ^c   Chen, Liang ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

AmpC; Ceftolozane tazobactam; G183D; Pseudomonas aeruginosa

Indexed keywords

BETA LACTAMASE AMPC; CEFTOLOZANE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIFUNGAL THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATION; CASE REPORT; CLINICAL ARTICLE; DRUG MECHANISM; HUMAN; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RECURRENT INFECTION; TERTIARY CARE CENTER; TREATMENT DURATION; WOUND DEHISCENCE; WOUND INFECTION; ANALOGS AND DERIVATIVES; DRUG EFFECT; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; PSEUDOMONAS INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; PENICILLANIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; WOUND INFECTION;

EID: 85035049407     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01183-17     Document Type: Article

References (12)

1. Thaden JT, Park LP, Maskarinec SA, Ruffin F, Fowler VG, Jr, van Duin D. 2017. Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa compared to other bacteria. Antimicrob Agents Chemother 61:e02671-16. https://doi.org/10.1128/AAC.02671-16.
2. van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation -lactam/-lactamase inhibitor combinations. Clin Infect Dis 63:234–241. https://doi.org/10.1093/cid/ciw243.
3. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. 2017. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother 61:e00465-17. https://doi.org/10.1128/AAC.00465-17.
4. Cabot G, Bruchmann S, Mulet X, Zamorano L, Moya B, Juan C, Haussler S, Oliver A. 2014. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 58:3091–3099. https://doi.org/10.1128/AAC.02462-13.
5. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, Doi Y, Hao B, Press EG, Cooper VS, Clancy CJ, Nguyen MH. 2017. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 65:110–120. https://doi.org/10.1093/cid/cix182.
6. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Merck Sharp & Dohme Corp. 2016. Zerbaxa package insert. Merck Sharp & Dohme Corp., Whitehouse Station, NJ. https://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf.
8. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, Sicheritz-Ponten T, Ussery DW, Aarestrup FM, Lund O. 2012. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol 50:1355–1361. https://doi.org/10.1128/JCM.06094-11.
9. Jolley KA, Maiden MC. 2010. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 11:595. https://doi.org/10.1186/1471-2105-11-595.
10. Allergan USA. 2017. Avycaz package insert. Allergan USA, Irvine, CA. https://www.allergan.com/assets/pdf/avycaz_pi.
11. KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
12. Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K, Tanudra MA, Nash TJ, Thresher J, Johnstone MR, Hajec L, Livchak S, McLaughlin RE, Alm RA. 2015. Selection and molecular characterization of ceftazidime/ avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 70:1650–1658. https://doi.org/10.1093/jac/dkv131.